Adaptive Biotechnologies ADPT Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's stock issuance proceeds?
- Adaptive Biotechnologies (ADPT) reported stock issuance proceeds of $5.03M in Q1 2026.
- How has Adaptive Biotechnologies's stock issuance proceeds changed year-over-year?
- Adaptive Biotechnologies's stock issuance proceeds decreased by 7.8% year-over-year, from $5.45M to $5.03M.
- What is the long-term trend for Adaptive Biotechnologies's stock issuance proceeds?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's stock issuance proceeds has grown at a -9.6% compound annual growth rate (CAGR), from $26.72M to $17.88M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.